Table 2. Univariate analysis of clinical factors for overall survival.
| Factors | HR (95% CI) | P value |
|---|---|---|
| Age (≥67/<67) | 0.86 (0.48–1.52) | 0.60 |
| Gender (female/male) | 1.58 (0.89–2.86) | 0.12 |
| Race (White/non-White) | 1.14 (0.65–2.02) | 0.64 |
| Current smoker (yes/no) | 0.87 (0.41–1.68) | 0.68 |
| Cardiac comorbidity (yes/no) | 1.11 (0.58–2.04) | 0.74 |
| Lung comorbidity (yes/no) | 1.04 (0.59–1.83) | 0.89 |
| Diabetes mellitus (yes/no) | 1.74 (0.11–3.26) | 0.09 |
| Histology (SCLC/NSCLC) | 1.21 (0.54–2.41) | 0.62 |
| GTV (≥98.6 cm3/<98.6 cm3) | 1.99 (1.12–3.63) | 0.02 |
| PTV (≥495.3 cm3/<495.3 cm3) | 1.41 (0.79–2.52) | 0.24 |
| Radiation dose (≥64 Gy/<64 Gy) | 0.79 (0.44–1.42) | 0.42 |
| Radiotherapy technique (IMRT/3D CRT) | 0.97 (0.39–2.07) | 0.95 |
| ECOG performance status (1–2/0) | 1.13 (0.62–2.16) | 0.69 |
| Charlson comorbidity index (≥2/<2) | 0.92 (0.49–1.66) | 0.79 |
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; GTV, gross tumor volume; PTV, planning target volume; 3D CRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; ECOG, Eastern Cooperative Oncology Group; Gy, gray; HR, hazard ratio; CI, confidence interval.